Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Interest & Investment Income (2016 - 2020)

Summit Therapeutics filings provide 7 years of Interest & Investment Income readings, the most recent being -$1000.0 for Q1 2020.

  • Quarterly Interest & Investment Income fell 138.41% to -$1000.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$1762.3 through Mar 2020, down 100.05% year-over-year, with the annual reading at $5000.0 for FY2019, N/A changed from the prior year.
  • Interest & Investment Income hit -$1000.0 in Q1 2020 for Summit Therapeutics, down from $1237.7 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.1 million in Q4 2017 and bottomed at -$3000.0 in Q2 2019.
  • Average Interest & Investment Income over 5 years is $435920.8, with a median of $2000.0 recorded in 2016.
  • The largest annual shift saw Interest & Investment Income surged 287432.19% in 2018 before it plummeted 200.0% in 2019.
  • Summit Therapeutics' Interest & Investment Income stood at $2000.0 in 2016, then plummeted by 99.47% to $10.63 in 2017, then skyrocketed by 34919055.5% to $3.7 million in 2018, then crashed by 99.97% to $1237.7 in 2019, then crashed by 180.8% to -$1000.0 in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Interest & Investment Income are -$1000.0 (Q1 2020), $1237.7 (Q4 2019), and $1000.0 (Q3 2019).